Background: Previous research has explored the cost of providing renal replacement therapies in patients with end-stage kidney disease and their quality of life. This is the first study to examine the healthcare costs of patients receiving conservative care without dialysis for end-stage kidney disease. This alternative to dialysis is an option for patients who prefer a supportive and palliative care approach. Aim: Descriptive cost and quality of life analyses alongside a UK-based multi-centre observational study in patients receiving conservative management for end-stage kidney disease. Design: Health service use was recorded up to 12 months after making the decision to receive conservative management. Mean costs were calculated for each 3-month time period. The annual cost was calculated in two ways: by using only patients with complete cost data and by using all available data weighted by the number of patients at each time point. Setting: In total, 42 patients who opted for conservative management over dialysis were recruited. Results: Mean costs were £1622 (0-3 months), £1008 (3-6 months), £554 (6-9 months) and £2626 (9-12 months). Mean annual cost based on complete data (n = 8) was £5511, and the weighted mean annual cost was £5620.
Introduction
End-stage kidney disease (ESKD) is a life-limiting disease associated with significantly increased morbidity and premature mortality. Providing dialysis to a growing, frail population with ESKD is a challenge faced by many countries particularly those with poor economic resources. 1 ESKD consumes approximately 2% of the United Kingdom's National Health Service (NHS) annual budget 2 and hospital-based haemodialysis costs up to £35,000 per person annually. 3 In the United States, hospital-based dialysis costs up to US$90,000 per person per year. 4 Evidence is emerging that offering dialysis to vulnerable, frail patients with additional comorbidities may be of little benefit in terms of quality of life or prolonging survival. [5] [6] [7] [8] An alternative to dialysis is conservative management (also known as supportive or palliative care), which offers a supportive approach to care delivered by a skilled multi-professional team 9 for 'prevention and relief of suffering by means of early identification and impeccable assessment and treatment of pain and other problems'. 10 Patients have the option to choose this pathway over dialysis. In addition, the Renal Physicians Association has updated practice guidance upholding the rights of patients not to commence dialysis. 11 In a study examining the use of conservative care via hospice services in dialysis patients in the United States, there was a reduction in the number of hospital visits compared to those who did not use hospices. 12 In contrast, patients with ESKD in the United Kingdom do not have easy access to hospice services.
In the Kidney Disease: Improving Global Outcomes (KDIGO) 'Controversies Conference on Supportive Care in Chronic Kidney', 10 conferees recommended supportive and palliative care be recognised as an important component of education for medical professionals in this field. For optimal delivery, appropriate patients should be identified with subsequent care based on need rather than solely on survival estimates. They also highlighted the importance of robust economic evaluation of kidney supportive care to inform resource allocation decisions within healthcare organisation. Research is needed into the costs and benefits of dialysis versus conservative kidney management for planning purposes and to aid decisions by patients and their families, 13 and there is a lack of data on the costs of providing conservative care. To do so requires information on the patient experience with regard to resource use when the conservative care approach is followed. This is important from a decision-making perspective in helping to inform treatment decisions and commissioning healthcare services. We were unable to find other studies that looked at resource use and costing in this population.
The Palliative Care in Chronic Kidney Disease (PACKS) study 14 was an observational study measuring several parameters, including health-related quality of life (HRQoL), satisfaction with decision-making 15 and costs of care, cognition, frailty and performance in patients with advanced chronic kidney disease managed without dialysis. The impact on carers in terms of burden and HRQoL was also studied. The study did not seek to compare treatment costs of dialysis versus conservative management, rather it aimed to explore the health and social care service use and quality of life of patients with ESKD who opt for conservative management and estimate costs to the NHS.
• • Patients may forgo dialysis in order to receive conservative management instead: a supportive approach to care. Costs associated with this have not been previously captured.
What this paper adds?
• • First study to examine health service use and costs alongside quality of life in patients receiving conservative management for ESKD. • • The prospective nature of the resource use logs meant increased transparency with regard to resource allocation, providing guidance as to where demands for healthcare resources were generated. • • Conservative management of ESKD is likely to be considerably less expensive than dialysis. 
Implications

Methods
Study design
The PACKS study 15 
Data collection
The economic analysis was undertaken from the perspective of the NHS and Personal Social Services (PSS) in line with the current recommendations set out by the National Institute for Health and Care Excellence 16 with additional data collected on carers paid for privately. Patients' use of health and social care services were measured over the study period using service use logs specifically developed for the PACKS study. Logs were provided at the baseline clinic visit by a research nurse, who provided guidance on completion. Patients were asked to record contacts with healthcare professionals in the community, hospital service use and formal care visits. They were asked to record whether hospital clinics and admissions were related to their disease. Estimates of the duration of general practitioner (GP) and hospital clinic appointments were also requested. Neither costs of informal care nor prescription use were included in the analysis. The logs were designed for self-completion by the patient but, if preferred, they could be completed by their carer or nurse. This was recorded on the log. It was not feasible to validate patient-reported data from administrative databases. Where fields on the returned logs were left blank, it was assumed that the patient did not use this particular service. In cases where optional 'Yes' and 'No' checkboxes were left blank, it was also assumed that these services were not used.
Individual-level health and social care service use was combined with unit costs to estimate costs for each participant. Unit costs were obtained from publicly available sources and set at 2015-2016 prices. These were the NHS Schedule of Reference Costs for hospital resources and the Unit Costs of Health and Social Care for general practice services 17, 18 (Table 1) . Descriptive statistics were used to summarise resource use and associated costs from 0 to 3, 3 to 6, 6 to 9 and 9 to 12 months, categorised according to community, hospital and carer services. The annual cost for each category was a weighted average based on the mean costs and number of patients at each time period. The total annual cost was calculated by summing the annual costs for each category.
Patients recruited later in the study were unable to complete logs at every time point due to study closure. Their data were censored as they had less than full follow-up in the study.
HRQoL was measured at baseline, 3, 6, 9 and 12 months using the generic Euroqol instrument the EQ-5D-5L, 19 and the EQ-5D-5L value set for England was used to obtain utility scores based on the responses. 20 
Results
In total. 42 patients were recruited between March 2015 and May 2016. Figure 1 shows the retention and dropout of participants. There were 42 patients with baseline data then 24, 16, 13 and 10 at each 3 month interval. Reasons for dropout included death and withdrawal of consent. In addition, follow-up on some participants was limited by end-of-study censoring.
Patient characteristics at baseline are summarised in Table 2 . The mean age of participants was 79.8 years, 59.5% (25/42) were female and 47.6% (20/42) were widowed. Mean eGFR at baseline was 12.47 mL/min/1.73 m 2 . There were eight patients recruited who died before the study ended: four of these before the first follow-up visit, two between 3-6 months, one between 6-9 months, and one person who dropped out between 6-9 months died between 9-12 months. At all time points, the majority of patients received staff assistance completing the log.
Use of health services
Total costs in each 3-month period by service type -carer, community and hospital -are presented in Table 3 , as well as the weighted 1-year average. Supplementary Table 1 gives a more detailed breakdown of the exact numbers of services used in each time period and their corresponding costs. The overall total costs per 3-month period were highest at 9-12 months, totalling £2626, of which 42% was accounted for by hospital and residential admissions. This was almost five times the total cost in the 6-to 9-month period. Figure 2 (displaying data from Table 3 ) shows the total costs for each period according to service type. Figure 2 illustrates that the highest proportion of costs were associated with clinic visits and hospital admissions in the 0-to 3-month and 9-to 12-month periods. Table 3 . Mean health service total costs (£UK) by service type for patients in the PACKS study. The rightmost bars of Figure 2 show the total 1-year cost for eight study participants who had complete cost data (i.e. completed all resource logs in the study) and a weighted average of costs over the 12-month period. In the former cohort, the total annual cost per patient was £5510, 57% of which was carer costs. In the latter, the weighted average was comparable at £5620, but hospital costs made up 55% of the total.
In one patient who died between 0 and 3 months, resource use was much higher than average: £3125 for the 3 months from baseline. In one of the patients who died before their 6-month visit, the cost of their resource use was £6819 and £2595 for 0-3 and 3-6 months, respectively. In both cases, these higher expenditures were driven primarily by hospital-associated costs. Table 4 shows the HRQoL of patients from baseline to 12 months using the EQ-5D-5L. The changes in means are illustrated in Figure 3 and demonstrate that the mean HRQoL was highest at 6 months (0.79) and lowest at 12 months (0.67) in those remaining in the study.
Health outcomes
Discussion
Main findings
This is the first study to examine health service use, costs and associated HRQoL in patients receiving conservative management for ESKD, now established as an alternative to maintenance dialysis. Barriers exist which impact recruiting participants with ESKD to renal research studies including frailty, fatigue, prognostic uncertainty, reluctance to discuss end-of-life and impending death. 13 This has led to poor knowledge of this population, which this article goes some way to address.
The average health service cost in the first year of the study (from the decision to receive conservative management and recruitment) was £5619, approximately one sixth of the cost of dialysis in the United Kingdom. 3 We recognise that if we had included a population of dialysis patients, eGFR would have fallen further prior to commencement of dialysis treatment, meaning the comparison of 1-year costs may not be like for like. That aside, the costings can be interpreted in light of this fact. The data show that costs were highest in the first and last periods, arguably reflecting higher service use linked with the setup and planning phase, then much higher service use associated with a small number of patients becoming more frail and dependent. The weighted mean estimated hospital care as the largest expenditure is in contrast to the estimate using patients with complete data where carers accounted for the majority. This was largely due to two patients receiving multiple daily home visits. We would emphasise that the decision to undergo dialysis or not by patients and clinicians must not be based solely on the cost of care, but a host of factors, some specific to the individual. However, this study highlights the importance of considering whether a patient will receive a sufficient gain in survival and/or HRQoL to justify the higher costs of dialysis compared to conservative management. On average, HRQoL declined over time, but this was not a substantial decrease. We suggest that the higher service use observed in the 9-to 12-month time period may reflect some deterioration in health state associated with progression of ESKD, the debilitating nature of the disease and increased frailty but requires further study. Use of services was lowest between 6 and 9 months, following the time point when patient EQ-5D-5L scores were at their peak, possibly showing a causal fall in service demand with higher HRQoL.
Strengths and limitations
Cost estimates were highly variable due to the small numbers of patients involved and should be interpreted with caution. Nevertheless, this observational study of clinical practice demonstrates that conservative management of ESKD is likely to be considerably less expensive than chronic dialysis. 3 The main reasons for dropout in the study included death and data censoring due to study closure. This suggests that the resource use logs and the EQ-5D-5L were acceptable, and the majority of patients left in the study did fill them in.
This study included data from nine renal units in the United Kingdom. Since most UK renal units offer conservative management or supportive and palliative care services for ESKD, it is likely that the costs identified are broadly similar in each UK region. However, only a minority of UK regions have funding specifically for conservative management. 13 A larger study could identify the predictors of specific resource use and associated costs using multiple regression methods, looking at factors like disease severity, comorbidities and demographic data. Patients were all recruited as they made a decision not to undergo dialysis, and while they have this in common, each individual would have been on a different trajectory in terms of their disease progression, how it affected them and their resource use. Therefore, focussing analysis on arbitrary 3-month time periods for patients is not comparing like with like but merely a window in time from when a choice was made. Ideally, patients would be followed from time of referral through to death, measuring resource use along the way, but this was not a feasible option. These time periods were chosen to capture as much data as possible, as patients were expected to drop out due to death and deteriorating health.
Collecting data on prescription medication use would also be useful if further studies of patients with ESKD to establish which drugs are prescribed and the contribution of medication to total costs. Extended follow-up period would be beneficial to capture longer term costs, to establish survival rates and how costs change as people approach death. The relationship between length of survival and costs could be analysed.
What this study adds
Descriptive cost analyses of this nature identify and measure the resource use that this population of patients incurs. Thus, the economic burden of given health problems on the overall population can be assessed. The design of the resource use log used in the study meant most health and social care services used by patients were captured. This 'bottom-up' approach measures healthcare utilisation data on a patient-level basis. The prospective nature of the service use log meant it could be filled in when visits occurred, rather than relying on recall at follow-up visits. Also, by administering the log in 3-month increments, it is easier to see when costs were incurred. The end result is transparency with regard to resource allocation, providing guidance as to where most demand is generated. Given that ESKD care is estimated to consume 2% of the annual NHS budget, it is important to know what specific services require funding. 2 Future studies could include direct comparison between dialysis and conservative management in terms of both costs and HRQoL, and a trial has begun with ESKD patients randomised to preparation pathways for responsive management or renal dialysis. 21 Using discrete choice experiments in this population would give an insight into the attributes important to patients in decision-making. This shows where patients are willing to make trade-offs between, for example, changes to duration of life versus HRQoL, as well as how the burden of treatment affects the treatment chosen. A literature review of discrete choice experiments in nephrology 22 reported attributes such as treatment timing, weekly hospital visits, life expectancy and type of care.
The results of the PACKS study 16, 17 will also be of interest to patient support groups who are active in making relevant stakeholders aware of the types of services required to treat ESKD and helping these develop. As well as this, many provide support to kidney units in the form of financial assistance for facilities but also to fund staff for caring purposes.
Conclusion
This is the first study to prospectively measure the health and social care use and costs of patients with ESKD who opt for conservative management. The study also provides valuable information for health and social care planning for patients with ESKD in both the United Kingdom and other countries with a comparable health service structure. Furthermore, it indicates that it is feasible to use self-report methods to collect service use and associated HRQoL from this patient population within a study setting.
